MMedication Read More FDA Panel Rejects Combo Drug for PTSD23 July 2025 An FDA advisory panel has resoundingly rejected the supplemental new drug application for the atypical antipsychotic brexpiprazole (Rexulti,…
MMedication Read More First New PTSD Drug in Two Decades On the Horizon?18 July 2025 The Psychopharmacologic Drugs Advisory Committee of the FDA is set to meet on July 18 to consider a…